1887

Abstract

A DNA vaccine containing the infectious BAC20 clone of serotype 1 Marek’s disease virus (MDV) was tested for its potential to protect against Marek’s disease (MD). Chickens were immunized at 1 day old with BAC20 DNA suspended either in PBS, as calcium phosphate precipitates, incorporated into chitosan nanoparticles, in DH10B cells, or bound to gold particles for gene-gun delivery. Challenge infection with MDV strain EU1 was performed at 12 days old, and four out of seven birds immunized with BAC20 DNA in saline by the intramuscular route remained free of MD until day 77 after challenge infection. A delay in the development of the disease could be observed in some animals vaccinated with other BAC20 DNA formulations, but clinical MD and tumour formation were evident in all but one bird. Five out of seven animals immunized with the vaccine virus CVI988 were protected against MD, but none out of seven birds survived EU1 challenge infection after injection of negative-control plasmid DNA. In a second animal experiment, five out of 12 chickens immunized with BAC20 DNA and six out of eight birds immunized with virus reconstituted from BAC20 DNA remained free of MD after challenge infection. In contrast, none out of 12 chickens survived challenge infection after immunization with BAC20 DNA lacking the essential gE gene or with gE-negative BAC20 virus. The results suggested that an MDV BAC DNA vaccine has potential to protect chickens against MD, but that reconstitution of vaccine virus is a prerequisite for protection.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-83-10-2367
2002-10-01
2020-09-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/83/10/0832367a.html?itemId=/content/journal/jgv/10.1099/0022-1317-83-10-2367&mimeType=html&fmt=ahah

References

  1. Adler H. E., DaMassa A. J.. 1979; Toxicity of endotoxin to chicks. Avian Diseases23:174–178
    [Google Scholar]
  2. Adler H., Messerle M., Wagner M., Koszinowski U. H.. 2000; Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome. Journal of Virology74:6964–6974
    [Google Scholar]
  3. Barrow A., Venugopal K.. 1999; Molecular characteristics of very virulent European MDV isolates. Acta Virologica43:90–93
    [Google Scholar]
  4. Becker Y., Tabor E., Asher Y., Davidson I., Malkinson M., Witter R. L.. 1993; PCR detection of amplified 132 bp repeats in Marek’s disease virus type 1 (MDV-1) DNA can serve as an indicator for critical genomic rearrangement leading to the attenuation of virus virulence. Virus Genes7:277–287
    [Google Scholar]
  5. Calnek B. W.. 2001; Pathogenesis of Marek’s disease virus infection. Current Topics in Microbiology and Immunology255:25–55
    [Google Scholar]
  6. Calnek B. W., Schat K. A., Peckham M. C., Fabricant J.. 1983; Field trials with a bivalent vaccine (HVT and SB-1) against Marek’s disease. Avian Diseases27:844–849
    [Google Scholar]
  7. Cui Z. Z., Yan D., Lee L. F.. 1990; Marek’s disease virus gene clones encoding virus-specific phosphorylated polypeptides and serological characterization of fusion proteins. Virus Genes3:309–322
    [Google Scholar]
  8. Cui Z., Qin A., Lee L. F., Wu P., Kung H. J.. 1999; Construction and characterization of a H19 epitope point mutant of MDV CVI988/Rispens strain. Acta Virologica43:169–173
    [Google Scholar]
  9. Davis H. L., McCluskie M. J.. 1999; DNA vaccines for viral diseases. Microbes and Infection1:7–21
    [Google Scholar]
  10. Davis H. L., Michel M. L., Mancini M., Schleef M., Whalen R. G.. 1994; Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. Vaccine12:1503–1509
    [Google Scholar]
  11. Delecluse H. J., Hammerschmidt W.. 1993; Status of Marek’s disease virus in established lymphoma cell lines: herpesvirus integration is common. Journal of Virology67:82–92
    [Google Scholar]
  12. Delecluse H. J., Schuller S., Hammerschmidt W.. 1993; Latent Marek’s disease virus can be activated from its chromosomally integrated state in herpesvirus-transformed lymphoma cells. EMBO Journal12:3277–3286
    [Google Scholar]
  13. Fynan E. F., Webster R. G., Fuller D. H., Haynes J. R., Santoro J. C., Robinson H. L.. 1993; DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proceedings of the National Academy of Sciences, USA90:11478–11482
    [Google Scholar]
  14. Fynan E. F., Webster R. G., Fuller D. H., Haynes J. R., Santoro J. C., Robinson H. L.. 1995; DNA vaccines: a novel approach to immunization. International Journal of Immunopharmacology17:79–83
    [Google Scholar]
  15. Gimeno I. M., Witter R. L., Reed W. M.. 1999; Four distinct neurologic syndromes in Marek’s disease: effect of viral strain and pathotype. Avian Diseases43:721–737
    [Google Scholar]
  16. Krishnan B. R.. 2000; Current status of DNA vaccines in veterinary medicine. Advanced Drug Delivery Reviews43:3–11
    [Google Scholar]
  17. Lee L. F., Witter R. L.. 1991; Humoral immune responses to inactivated oil-emulsified Marek’s disease vaccine. Avian Diseases35:452–459
    [Google Scholar]
  18. Lee L. F., Wu P., Sui D., Ren D., Kamil J., Kung H. J., Witter R. L.. 2000; The complete unique long sequence and the overall genomic organization of the GA strain of Marek’s disease virus. Proceedings of the National Academy of Sciences, USA97:6091–6096
    [Google Scholar]
  19. Messerle M., Crnkovic I., Hammerschmidt W., Ziegler H., Koszinowski U. H.. 1997; Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proceedings of the National Academy of Sciences, USA94:14759–14763
    [Google Scholar]
  20. Morgan R. W., Cantello J. L., McDermott C. H.. 1990; Transfection of chicken embryo fibroblasts with Marek’s disease virus DNA. Avian Diseases34:345–351
    [Google Scholar]
  21. Nazerian K., Lee L. F., Yanagida N., Ogawa R.. 1992; Protection against Marek’s disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek’s disease virus. Journal of Virology66:1409–1413
    [Google Scholar]
  22. Nazerian K., Witter R. L., Lee L. F., Yanagida N.. 1996; Protection and synergism by recombinant fowl pox vaccines expressing genes from Marek’s disease virus. Avian Diseases40:368–376
    [Google Scholar]
  23. Niikura M., Matsuura Y., Endoh D., Onuma M., Mikami T.. 1992; Expression of the Marek’s disease virus (MDV) homolog of glycoprotein B of herpes simplex virus by a recombinant baculovirus and its identification as the B antigen (gp100, gp60, gp49) of MDV. Journal of Virology66:2631–2638
    [Google Scholar]
  24. Osterrieder N., Wagner R., Brandmüller C., Schmidt P., Wolf H., Kaaden O. R.. 1995; Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). Virology208:500–510
    [Google Scholar]
  25. Rispens B. H., van Vloten H., Mastenbroek N., Maas H. J., Schat K. A.. 1972a; Control of Marek’s disease in the Netherlands. I. Isolation of an avirulent Marek’s disease virus (strain CVI 988) and its use in laboratory vaccination trials. Avian Diseases16:108–125
    [Google Scholar]
  26. Rispens B. H., van Vloten H., Mastenbroek N., Maas J. L., Schat K. A.. 1972b; Control of Marek’s disease in the Netherlands. II. Field trials on vaccination with an avirulent strain (CVI 988) of Marek’s disease virus. Avian Diseases16:126–138
    [Google Scholar]
  27. Robinson H. L., Torres C. A.. 1997; DNA vaccines. Seminars in Immunology9:271–283
    [Google Scholar]
  28. Roy K., Mao H. Q., Huang S. K., Leong K. W.. 1999; Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nature Medicine5:387–391
    [Google Scholar]
  29. Sambrook J., Fritsch D. F., Maniatis T.. 1989; Molecular Cloning: a Laboratory Manual , 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory;
    [Google Scholar]
  30. SAS Institute Inc. 1984; SAS/STAT User’s Guide, Version 6 Cary, NC: SAS Institute Inc;
    [Google Scholar]
  31. Schat K. A., Markowski-Grimsrud C. J.. 2001; Immune responses to Marek’s disease virus infection. Current Topics in Microbiology and Immunology255:91–120
    [Google Scholar]
  32. Schat K. A., Calnek B. W., Fabricant J.. 1982; Characterisation of two highly oncogenic strains of Marek’s disease virus. Avian Pathology11:593–605
    [Google Scholar]
  33. Schumacher D., Tischer B. K., Fuchs W., Osterrieder N.. 2000; Reconstitution of Marek’s disease virus serotype 1 (MDV-1) from DNA cloned as a bacterial artificial chromosome and characterization of a glycoprotein B-negative MDV-1 mutant. Journal of Virology74:11088–11098
    [Google Scholar]
  34. Schumacher D., Tischer B. K., Reddy S. M., Osterrieder N.. 2001; Glycoproteins E and I of Marek’s disease virus serotype 1 are essential for virus growth in cultured cells. Journal of Virology75:11307–11318
    [Google Scholar]
  35. Schumacher D., Tischer B. K., Teifke J.-P., Wink K., Osterrieder N.. 2002; Generation of a permanent cell line that supports efficient growth of Marek’s disease virus (MDV) by constitutive expression of MDV glycoprotein C. Journal of General Virology83:1987–1992
    [Google Scholar]
  36. Sharma J. M.. 1971; In vitro cell association of Marek’s disease herpesvirus. American Journal of Veterinary Research32:291–301
    [Google Scholar]
  37. Stokes M. E., Davis C. S., Koch G. G.. 2000; Categorical Data Analysis Using the SAS System Cary, NC: SAS Institute Inc;
    [Google Scholar]
  38. Suter M., Lew A. M., Grob P., Adema G. J., Ackermann M., Shortman K., Fraefel C.. 1999; BAC-VAC, a novel generation of (DNA) vaccines: a bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1. Proceedings of the National Academy of Sciences, USA96:12697–12702
    [Google Scholar]
  39. Tulman E. R., Afonso C. L., Lu Z., Zsak L., Rock D. L., Kutish G. F.. 2000; The genome of a very virulent Marek’s disease virus. Journal of Virology74:7980–7988
    [Google Scholar]
  40. Witter R. L.. 1982; Protection by attenuated and polyvalent vaccines against highly virulent strains of Marek’s disease virus. Avian Pathology11:49–62
    [Google Scholar]
  41. Witter R. L.. 1983; Characteristics of Marek’s disease viruses isolated from vaccinated commercial chicken flocks: association of viral pathotype with lymphoma frequency. Avian Diseases27:113–132
    [Google Scholar]
  42. Witter R. L.. 1992; Safety and comparative efficacy of the CVI988/Rispens vaccine strain. In Proceedings of the WPA pp315–319 Amsterdam: World’s Poultry Science Association;
    [Google Scholar]
  43. Witter R. L.. 1997; Increased virulence of Marek’s disease virus field isolates. Avian Diseases41:149–163
    [Google Scholar]
  44. Witter R. L.. 2001; Protective efficacy of Marek’s disease vaccines. Current Topics in Microbiology and Immunology255:57–90
    [Google Scholar]
  45. Witter R. L., Lee L. F.. 1984; Polyvalent Marek’s disease vaccines: safety, efficacy and protective synergism in chicken with maternal antibodies. Avian Pathology13:75–92
    [Google Scholar]
  46. Witter R. L., Lee L. F., Fadly A. M.. 1995; Characteristics of CVI988/Rispens and R2/23, two prototype vaccine strains of serotype 1 Marek’s disease virus. Avian Diseases39:269–284
    [Google Scholar]
  47. Yokoyama H., Peralta R. C., Sendo S., Ikemori Y., Kodama Y.. 1993; Detection of passage and absorption of chicken egg yolk immunoglobulins in the gastrointestinal tract of pigs by use of enzyme-linked immunosorbent assay and fluorescent antibody testing. American Journal of Veterinary Research54:867–872
    [Google Scholar]
  48. Zhu G. S., Ojima T., Hironaka T., Ihara T., Mizukoshi N., Kato A., Ueda S., Hirai K.. 1992; Differentiation of oncogenic and nononcogenic strains of Marek’s disease virus type 1 by using polymerase chain reaction DNA amplification. Avian Diseases36:637–645
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-83-10-2367
Loading
/content/journal/jgv/10.1099/0022-1317-83-10-2367
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error